LNK01006 / Lynk Pharmaceuticals - LARVOL DELTA

Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006 (PRNewswire) - "The asset will be developed within Formation Bio's newly formed subsidiary Bleecker Bio....Formation Bio plans to initiate a Phase 1 study in the first half of 2026, reflecting the company's growing momentum in building a diverse portfolio of high-potential, clinical-stage assets....Under the terms of the agreement, Lynk Pharmaceuticals will receive a minority equity stake in Bleecker Bio, an upfront payment and additional development, regulatory, and commercial milestones totaling up to $605 million US dollars and tiered royalties on potential future sales."

Licensing / partnership • New P1 trial • Immunology • Inflammation

Lynk Pharmaceuticals Announces FDA IND Approval of Its Allosteric TYK2 Inhibitor LNK01006 (PRNewswire) - "LNK01006 is a highly brain-penetrant, potent, and selective oral TYK2 allosteric inhibitor targeting the JH2 domain....'Supported by strong evidence from human genetics and patient gene-expression studies and by robust efficacy in preclinical neuroinflammation models, LNK01006 represents a promising new therapeutic approach for CNS diseases with significant unmet need. We look forward to advancing its clinical validation'."

IND • CNS Disorders • Inflammation